BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chandra S, Zheng Y, Pandya S, Yu T, Kearney M, Wang L, Kim R, Phatak H. Real-world outcomes among US Merkel cell carcinoma patients initiating immune checkpoint inhibitors or chemotherapy. Future Oncol 2020;16:2521-36. [PMID: 32883109 DOI: 10.2217/fon-2020-0453] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Tanda ET, d'Amato AL, Rossi G, Croce E, Boutros A, Cecchi F, Spagnolo F, Queirolo P. Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale? Front Oncol 2021;11:739006. [PMID: 34631574 DOI: 10.3389/fonc.2021.739006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Mazziotta C, Lanzillotti C, Torreggiani E, Oton-Gonzalez L, Iaquinta MR, Mazzoni E, Gaboriaud P, Touzé A, Silvagni E, Govoni M, Martini F, Tognon M, Rotondo JC. Serum Antibodies Against the Oncogenic Merkel Cell Polyomavirus Detected by an Innovative Immunological Assay With Mimotopes in Healthy Subjects. Front Immunol 2021;12:676627. [PMID: 34168646 DOI: 10.3389/fimmu.2021.676627] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
3 Zheng Y, Yu T, Mackey RH, Gayle JA, Wassel CL, Phatak H, Kim R. Clinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy. Clinicoecon Outcomes Res 2021;13:213-26. [PMID: 33790597 DOI: 10.2147/CEOR.S290768] [Reference Citation Analysis]